This is Local London | Obinutuzumab routs rituximab in older chronic lymphocytic leukemia patients The Oncology Report In the CLL11 study of older chronic lymphocytic leukemia (CLL) patients with coexisting medical problems, obinutuzumab (Gazyva) pushed the overall response rate to 78%, compared with 65% with rituximab (Rituxan) (P less than .0001). Both drugs were ... Obinutuzumab Tops Rituximab in CLL Trial Dr. Goede on Obinutuzumab Versus Rituximab in CLL New Drug Combo Potentially 'Practice Changing' in CLL |
